Clinical, Molecular and Metabolic Characteristics of Parkinson's Disease (PD) Patients With Parkin Mutation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Groupe Hospitalier Pitie-Salpetriere.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Délégation Régionale à la Recherche Clinique
Information provided by:
Groupe Hospitalier Pitie-Salpetriere
ClinicalTrials.gov Identifier:
NCT00169364
First received: September 12, 2005
Last updated: August 28, 2007
Last verified: September 2005
  Purpose

Parkinson's disease is a frequent neurodegenerative disorder. Genetic forms of the disease have been recently identified. The monogenic form due to parkin mutation is responsible for many familial cases and sporadic forms. However, the relationship between the mutation and the genotype of patients is not fully established. The aim of this study is to compare clinical, metabolic and neuropsychological characteristics obtained in patients with parkin mutation with those of patients without parkin mutation.


Condition Intervention
Parkinson's Disease
Device: positron emission tomography

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Comparison of Clinical, Molecular and Metabolic Characteristics of PD Patients With and Without Parkin Mutation

Resource links provided by NLM:


Further study details as provided by Groupe Hospitalier Pitie-Salpetriere:

Primary Outcome Measures:
  • Parkin mutation
  • Motor disability
  • Neuropsychological evaluation
  • Psychiatric evaluation

Secondary Outcome Measures:
  • Positron emission tomography

Estimated Enrollment: 50
Study Start Date: May 2002
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Juvenile Parkinson's disease (< 45 years)
  • Parkin mutation
  • Normal brain magnetic resonance imaging (MRI)

Exclusion Criteria:

  • Contraindication to brain MRI
  • Women without effective contraception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00169364

Contacts
Contact: Alexis Brice, MD, PhD 33-142162183 brice@ccr.jussieu.fr

Locations
France
Centre d'Investigation Clinique-Hôpital Pitié-Salpetriere Recruiting
Paris, France
Contact: Marie-Laure Welter, MD    33-142161950    marie-laure.welter@psl.aphp.fr   
Principal Investigator: Alexis Brice, MD, PhD         
Sponsors and Collaborators
Groupe Hospitalier Pitie-Salpetriere
Délégation Régionale à la Recherche Clinique
Investigators
Study Director: Alexis Brice, MD, PhD Groupe Hospitalier Pitié-Salpêtrière
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00169364     History of Changes
Other Study ID Numbers: P011104
Study First Received: September 12, 2005
Last Updated: August 28, 2007
Health Authority: France: Ministry of Health

Keywords provided by Groupe Hospitalier Pitie-Salpetriere:
Parkinson's disease
parkin mutation
Juvenile parkinson's disease
positron emission tomography

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders

ClinicalTrials.gov processed this record on October 23, 2014